Hospital
Tahoe Forest Hospital District
Tahoe Forest Hospital District was paid $5.09M by Medicaid between Jan 2018 and Nov 2024, across 145 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 19% of everything it billed.
33Billing provider infoTAHOE FOREST HOSPITAL DISTRICT
TRUCKEE, CA 96161
TRUCKEE, CA 96161
33aNPI1538265780assigned 09/15/2006
33bProvider typeCritical Access Hospital
28Total paid$5.09M
24GClaims170,319
24DCodes billed145
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in California
Rank by total paid#10 of 30
Median peer was paid$3.14M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,536 | $453K | |
| 2019 | 20,904 | $507K | |
| 2020 | 16,264 | $388K | |
| 2021 | 24,697 | $659K | |
| 2022 | 32,148 | $865K | |
| 2023 | 30,435 | $821K | |
| 2024incomplete | 26,335 | $1.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 19% | 24,758 | 5,834 | $943K |
| 0450 | Emergency room services | 7.7% | 6,978 | 6,266 | $390K |
| 97139 | 6.7% | 11,379 | 2,131 | $342K | |
| 97750 | 5.6% | 3,871 | 2,622 | $286K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 5.0% | 1,557 | 1,438 | $253K |
| 80053 | Comprehensive metabolic panel | 4.3% | 12,199 | 10,714 | $220K |
| 99199 | Unlisted special service, procedure or report | 4.1% | 3,909 | 3,502 | $207K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.0% | 1,560 | 741 | $155K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.9% | 1,558 | 1,200 | $147K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 2,227 | 1,733 | $140K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.5% | 1,617 | 1,550 | $126K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.3% | 540 | 531 | $118K |
133 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 12,584 | $114K |
| 97010 | 2.1% | 1,379 | $105K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 527 | $102K |
| 0250 | 1.9% | 8,176 | $99K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.9% | 4,979 | $98K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 2,114 | $90K |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 10,355 | $73K |
| 80061 | Lipid panel | 1.1% | 4,006 | $54K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.0% | 554 | $53K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,553 | $48K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 411 | $46K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,902 | $41K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 87 | $40K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 424 | $38K |
| 99283 | Emergency room visit (moderate) | <1% | 441 | $37K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,974 | $37K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,065 | $32K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 799 | $32K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 166 | $32K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,161 | $25K |
| 97165 | <1% | 183 | $21K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,754 | $20K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 852 | $19K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 582 | $18K |
| 97799 | <1% | 516 | $18K | |
| 84439 | <1% | 1,601 | $17K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,326 | $17K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 661 | $16K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 142 | $16K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 175 | $15K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,108 | $15K |
| 97113 | <1% | 275 | $14K | |
| 76830 | Ultrasound, transvaginal | <1% | 109 | $13K |
| 71045 | Radiologic examination, chest; single view | <1% | 575 | $13K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 56 | $12K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $12K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 110 | $12K |
| 83690 | <1% | 1,460 | $12K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,584 | $11K |
| 86803 | <1% | 667 | $11K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 372 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 393 | $11K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 629 | $10K |
| 85027 | <1% | 1,387 | $10K | |
| 81001 | <1% | 2,088 | $9K | |
| 87081 | <1% | 1,155 | $9K | |
| 84484 | <1% | 699 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 158 | $8K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 547 | $8K |
| 99070 | <1% | 362 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,335 | $7K |
| Z7610 | <1% | 714 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 329 | $7K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 718 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,104 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 315 | $6K |
| 81513 | <1% | 88 | $6K | |
| Z7502 | <1% | 160 | $6K | |
| 87340 | <1% | 459 | $5K | |
| 0258 | <1% | 907 | $5K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 853 | $5K |
| 81025 | <1% | 892 | $5K | |
| 99284 | Emergency room visit (serious) | <1% | 145 | $5K |
| J3490 | Unclassified drugs | <1% | 777 | $4K |
| 84466 | <1% | 350 | $4K | |
| 86140 | <1% | 774 | $4K | |
| 87070 | <1% | 422 | $4K | |
| 87481 | <1% | 152 | $4K | |
| 80305 | <1% | 112 | $4K | |
| 99285 | Emergency room visit (most serious) | <1% | 122 | $4K |
| 82728 | <1% | 339 | $4K | |
| 87186 | <1% | 492 | $4K | |
| 82077 | <1% | 198 | $3K | |
| 85652 | <1% | 989 | $3K | |
| 81002 | <1% | 895 | $3K | |
| 76642 | <1% | 26 | $3K | |
| 84153 | <1% | 152 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 16 | $3K |
| 87077 | <1% | 407 | $3K | |
| 83540 | <1% | 395 | $3K | |
| 82607 | <1% | 270 | $3K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 25 | $2K |
| 76536 | <1% | 13 | $2K | |
| 83880 | <1% | 83 | $2K | |
| 81003 | <1% | 727 | $2K | |
| 85610 | <1% | 427 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 28 | $2K |
| 87799 | <1% | 68 | $2K | |
| 92650 | <1% | 26 | $2K | |
| 87512 | <1% | 154 | $1K | |
| 82570 | <1% | 300 | $1K | |
| 73610 | <1% | 25 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 26 | $1K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 170 | $1K |
| 0272 | <1% | 758 | $1K | |
| 0270 | <1% | 542 | $1K | |
| 83735 | <1% | 199 | $1K | |
| Z1034 | <1% | 20 | $1K | |
| 0710 | <1% | 15 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 31 | $1K |
| Z7500 | <1% | 37 | $1K | |
| 73030 | <1% | 29 | $838.86 | |
| 92586 | <1% | 12 | $832.80 | |
| 86780 | <1% | 89 | $822.94 | |
| 73110 | <1% | 25 | $770.74 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 138 | $755.02 |
| 82043 | <1% | 113 | $693.69 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 46 | $666.49 |
| 86850 | <1% | 54 | $631.55 | |
| 85379 | <1% | 52 | $624.52 | |
| J2704 | Injection, propofol, 10 mg | <1% | 179 | $598.74 |
| 86901 | <1% | 111 | $522.80 | |
| 80143 | <1% | 26 | $497.88 | |
| 90686 | <1% | 16 | $382.87 | |
| 87040 | <1% | 18 | $309.92 | |
| 86900 | <1% | 84 | $307.74 | |
| 80179 | <1% | 25 | $279.94 | |
| 80076 | <1% | 38 | $272.58 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 47 | $269.40 |
| 84550 | <1% | 58 | $266.15 | |
| 86704 | <1% | 24 | $262.60 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 27 | $262.23 |
| 86762 | <1% | 12 | $182.57 | |
| 82746 | <1% | 13 | $169.91 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 33 | $155.74 |
| 83615 | <1% | 14 | $92.51 | |
| 84702 | <1% | 12 | $91.33 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 20 | $79.96 |
| 82950 | <1% | 14 | $64.77 | |
| 87147 | <1% | 15 | $42.97 | |
| 87205 | <1% | 12 | $41.84 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 21 | $33.95 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBETTS, CRYSTAL (CFO)
Parent organizationTAHOE FOREST HOSPITAL DISTRICT
| Provider | Location | Paid |
|---|---|---|
| Tahoe Forest Hospital District | Truckee, CA | $6.02M |
| Tahoe Forest Hospital District | Truckee, CA | $4.89M |
| Tahoe Forest Hospital District | Truckee, CA | $2.01M |
| Tahoe Forest Hospital District | Truckee, CA | $697K |
| Tahoe Forest Hospital District | Incline Village, NV | $445K |
| Tahoe Forest Hospital District | Truckee, CA | $266K |
| Tahoe Forest Hospital District | Truckee, CA | $176K |
| Tahoe Forest Hospital District | Incline Village, NV | $107K |
| Tahoe Forest Hospital District | Truckee, CA | $32K |
| Tahoe Forest Hospital District | Truckee, CA | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.